Literature DB >> 20622649

Rectal dose constraints for intensity modulated radiation therapy of the prostate.

Gregory P Swanson1, Sotirios Stathakis.   

Abstract

Prostate dose escalation appears to have resulted in increased cancer control. Such escalation has been made possible by the ability to deliver more conformal treatment that spares normal tissue from the higher radiation doses. The supposition is that this has enabled higher doses, but without an increase in toxicity. The most disabling toxicity in prostate cancer radiotherapy is rectal. We evaluated the current status of conformal radiation and late rectal toxicity with the goal of determining whether reasonable rectal dose and volume constraints can be determined. Although the literature is inexact, we believe that some generalized constraints can be recommended and show that those recommendations are consistent with what is being used at experienced centers.

Entities:  

Mesh:

Year:  2011        PMID: 20622649     DOI: 10.1097/COC.0b013e3181dbb993

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer.

Authors:  T Jonathan Yang; Jung Hun Oh; Christina H Son; Aditya Apte; Joseph O Deasy; Abraham Wu; Karyn A Goodman
Journal:  Gastrointest Cancer Res       Date:  2013-09

2.  Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer.

Authors:  Kazuki Kotabe; Hidetsugu Nakayama; Aruga Takashi; Atsuko Takahashi; Tsuyoshi Tajima; Haruki Kume
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

3.  Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference?

Authors:  David J Byun; Daniel J Gorovets; Lauren M Jacobs; Laura Happersett; Pengpeng Zhang; Xin Pei; Sarah Burleson; Zhigang Zhang; Margie Hunt; Sean McBride; Marisa A Kollmeier; Michael J Zelefsky
Journal:  Radiat Oncol       Date:  2020-10-16       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.